Kozyrskyj A L, Mustard C A, Cheang M S, Simons F E
Department of Community Health Sciences, Manitoba Centre for Health Policy and Evaluation, Faculty of Medicine, University of Manitoba, Winnipeg, Man.
CMAJ. 2001 Oct 2;165(7):897-902.
Drug benefit policies are an important determinant of a population's use of prescription drugs. This study was undertaken to determine whether a change in a provincial drug benefit policy, from a fixed deductible and copayment system to an income-based deductible system, resulted in changes in receipt of prescriptions for inhaled corticosteroids by Manitoba children with asthma.
Using Manitoba's health care administrative databases, we identified a population-based cohort of 10,703 school-aged children who met our case definition for asthma treatment before and after the province's drug benefit policy was changed in April 1996. The effects of the program change on the probability of receiving a prescription for an inhaled corticosteroid and on the mean number of inhaled corticosteroid doses dispensed were compared between a group of children insured under other drug programs (the comparison group) and 2 groups of children insured under the deductible program: those living in low-income neighbourhoods and those living in higher-income neighbourhoods. All analyses were adjusted for a measure of asthma severity.
For higher-income children with severe asthma who were covered by the deductible program, the probability of receiving an inhaled corticosteroid prescription and the mean annual number of inhaled corticosteroid doses declined after the change to the drug policy. A trend toward a decrease in receipt of prescriptions was also observed for low-income children, but receipt of prescriptions was unaltered in the comparison group. Before the policy change, among children with severe asthma, the mean annual number of inhaled corticosteroid doses was lowest for low-income children, and this pattern persisted after the change. Among children with mild to moderate asthma, those covered by the deductible program (both low income and higher income) were less likely to receive prescriptions for inhaled corticosteroids than those in the comparison group, and this difference was statistically significant for the higher-income children.
The change to an income-based drug benefit policy was associated with a decrease in the use of inhaled corticosteroids by higher-income children with severe asthma and did not improve use of these drugs by low-income children.
药物福利政策是人群使用处方药的一个重要决定因素。本研究旨在确定省级药物福利政策从固定免赔额和共付额制度转变为基于收入的免赔额制度后,曼尼托巴省哮喘儿童吸入性糖皮质激素处方的获取情况是否发生变化。
利用曼尼托巴省的医疗保健管理数据库,我们确定了一个基于人群的队列,其中有10703名学龄儿童,他们在1996年4月该省药物福利政策改变前后符合我们对哮喘治疗的病例定义。在一组参加其他药物计划的儿童(对照组)与两组参加免赔额计划的儿童(居住在低收入社区的儿童和居住在高收入社区的儿童)之间,比较了计划变更对吸入性糖皮质激素处方获取概率以及吸入性糖皮质激素配药平均剂量的影响。所有分析都针对哮喘严重程度进行了调整。
对于参加免赔额计划的高收入重度哮喘儿童,药物政策改变后,吸入性糖皮质激素处方的获取概率和吸入性糖皮质激素的年平均剂量均有所下降。低收入儿童也观察到处方获取量有下降趋势,但对照组的处方获取量未改变。在政策改变之前,重度哮喘儿童中,低收入儿童吸入性糖皮质激素的年平均剂量最低,这种模式在政策改变后依然存在。在轻度至中度哮喘儿童中,参加免赔额计划的儿童(包括低收入和高收入)比对照组儿童获得吸入性糖皮质激素处方的可能性更小,对于高收入儿童,这种差异具有统计学意义。
向基于收入的药物福利政策的转变与高收入重度哮喘儿童吸入性糖皮质激素使用的减少有关,且并未改善低收入儿童对这些药物的使用情况。